



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 37/02 (2006.01)
A61P 35/00 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2024/085100

(22) International Filing Date:

06 December 2024 (06.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2318820.4 08 December 2023 (08.12.2023) GB

(71) Applicant: UCB BIOPHARMA SRL [BE/BE]; Allée de la Recherche 60, 1070 Brussels (BE).

(72) Inventors: BITHELL, Rosemary Frances; C/O IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). BOWSHER, Leo Alexander; C/O IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). HUMPHREYS, David Paul; C/O IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). RAPECKI, Stephen Edward; C/O IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE

(GB). TYSON, Kerry Louise; C/O IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB).


(74) Agent: J A KEMP LLP; 80 Turnmill Street, London EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ANTIBODIES

Figure 1: Comparison of the ability of 17415, 17552 and 4133 monoclonal antibodies to kill PBMC cells expressing CD45



(57) Abstract: The present invention provides in particular antibodies or antigen-binding fragments thereof which are specific for CD45. The antibodies include antibodies that are monospecific for CD45, as well as antibodies that are biparatopic for CD45. The antibodies are typically able to bind both human and cynomolgus monkey CD45. The antibodies of the invention have various uses involving targeting, depleting, and killing cells expressing CD45, particularly for the treatment of cancer or autoimmune diseases which are mediated by CD45 positive cells or prior to the transplant of cells.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*